drugset / Trial / NCT01179529

Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

NCT01179529 ↗

Phase 2 Completed Technical University of Munich
NaSingle-groupTreatment

Summary

This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody — —

Indications